Stocks and Investing Stocks and Investing
Mon, October 17, 2011
[ Mon, Oct 17th 2011 ] - Market Wire
Result of Annual Meeting
[ Mon, Oct 17th 2011 ] - Market Wire
Fundraising Growth Slows

Market Maker Surveillance Report. BEXP, SQNM, MS, ANDS, EP, KOG, Bullishly Biased Price Friction For Monday, October 17th 2011


Published on 2011-10-17 18:00:48 - WOPRAI
  Print publication without navigation


October 17, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3983 companies with "abnormal" market making, 1566 companies with positive Friction Factors and 4300 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. BRIGHAM EXPLORATION CO (NASDAQ:BEXP), SEQUENOM INC (NASDAQ:SQNM), MORGAN STANLEY (NYSE:MS), ANADYS PHARMACEUTICALS INC (NASDAQ:ANDS), EL PASO CORP (NYSE:EP), KODIAK OIL & GAS CORP (NYSE:KOG). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     BEXP       $6.390       21.05%       27,708,961      44.50%       34,166,920      54.87%       -6,457,959      Abnormal
     SQNM       $0.230       4.32%        2,619,254       42.38%       3,502,810       56.68%       -883,556        Abnormal
     MS         $0.060       0.39%        8,289,868       28.50%       9,738,280       33.48%       -1,448,412      Abnormal
     ANDS       $2.610       250.48%      15,096,355      32.95%       30,704,072      67.02%       -15,607,717     Abnormal
     EP         $4.820       24.60%       28,933,358      31.65%       30,654,626      33.53%       -1,721,268      Abnormal
     KOG        $0.240       4.54%        3,897,351       33.74%       4,325,574       37.44%       -428,223        Abnormal
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above had more selling than buying on Monday and their stock prices rose. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows BEXP with 6,457,959 greater shares of selling than buying (NetVol) and the stock price was up $6.39000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more selling than buying should cause prices to drop.

BRIGHAM EXPLORATION CO (NASDAQ:BEXP) - Brigham Exploration Company engages in the exploration, development, and production of onshore oil and natural gas reserves in the Rocky Mountains, the Gulf Coast, the Anadarko Basin, and west Texas. It holds property interests in the Powder River Basin located in Wyoming; Onshore Gulf Coast consisting of the Vicksburg trend in Brooks County, Texas; Miocene and Upper Oligocene trends in Southern Louisiana; and the Frio trend in and around Matagorda County, Texas. As of December 31, 2009, the company had estimated proved reserves of 27.7 MMBoe. It had approximately 282,584 net leasehold acres in the Williston Basin. The company sells its oil and natural gas to intrastate pipeline purchasers, operators of processing plants, and marketing companies. Brigham Exploration Company was founded in 1990 and is based in Austin, Texas.

SEQUENOM INC (NASDAQ:SQNM) - Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock. The company operates in two segments, Genetic Analysis and Molecular Diagnostics. The Genetic Analysis segment designs and markets MassARRAY system, a high performance nucleic acid analysis platform that comprises hardware, software applications, consumable chips, and reagents to measure genetic target material and variations. This segment offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. It also provides iPLEX multiplexing assay, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. The Genetic Analysis segment offers its products through direct sales, support personnel, and distribution partners to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and various government agencies worldwide. The Molecular Diagnostics segment researches, develops, and commercializes noninvasive molecular diagnostic tests for prenatal genetic disorders and diseases, womens health related disorders and diseases, age-related macular degeneration diagnostics, oncology, infectious diseases, and other diseases and disorders. This segment markets diagnostic technology for prenatal diagnostics under the trademark SEQureDx. The company was founded in 1994 and is headquartered in San Diego, California.

MORGAN STANLEY (NYSE:MS) - Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. It operates in three segments: Institutional Securities, Global Wealth Management Group, and Asset Management. The Institutional Securities segment offers financial advisory services on mergers and acquisitions, divestitures, joint ventures, corporate restructurings, recapitalizations, spin-offs, exchange offers, and leveraged buyouts and takeover defenses, as well as shareholder relations, capital raising, corporate lending, and investments. This segment also engages in sales, trading, financing, and market-making activities, including equity trading, commodities, and interest rates, credit, and currencies, as well as financing services, such as prime brokerage, consolidated clearance, settlement, custody, financing, and portfolio reporting services. The Global Wealth Management Group segment provides brokerage and investment advisory services covering various investment alternatives comprising equities, options, futures, foreign currencies, precious metals, fixed income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs; education savings programs, financial and wealth planning services, and annuity and insurance products; credit and other lending products; cash management services; retirement services; and trust and fiduciary services. The Asset Management segment offers products and services in equity, fixed income, and alternative investments, such as hedge funds, fund of funds, real estate, private equity, and infrastructure to institutional and retail clients through proprietary and third party distribution channels. This segment also involves in investment and merchant banking activities. The company was founded in 1935 and is headquartered in New York.

ANADYS PHARMACEUTICALS INC (NASDAQ:ANDS) - Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, a Phase I trial product, an oral toll-like receptor 7 for the treatment of hepatitis C and cancer. The company was formerly known as Scriptgen Pharmaceuticals, Inc. and changed its name to Anadys Pharmaceuticals, Inc. in May 2000. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California.

EL PASO CORP (NYSE:EP) - El Paso Corporation operates in the natural gas transmission, and exploration and production sectors of the energy industry primarily in the United States. It offers natural gas transmission services to a range of customers, including natural gas producers, marketers, and end-users, as well as other natural gas transmission, distribution, and electric generation companies through its interests in approximately 42,000 miles of interstate pipeline system. The company also operates approximately 230 billion cubic feet of storage capacity, and an LNG receiving terminal and related facilities in Elba Island, Georgia. El Paso also focuses on the exploration, acquisition, development, and production of natural gas, oil, and natural gas liquids in the United States, Brazil, and Egypt. As of December 31, 2009, it held an estimated 2.75 trillion cubic feet of natural gas equivalents of proved natural gas and oil reserves. El Paso Corporation has a joint venture agreement with AGL Resources Inc. to distribute liquefied natural gas (LNG) across the southeastern United States to the heavy-duty transportation market. The company was founded in 1928 and is based in Houston, Texas.

KODIAK OIL & GAS CORP (NYSE:KOG) - Kodiak Oil & Gas Corp., an independent energy company, engages in the exploration, exploitation, development, acquisition, and production of natural gas and crude oil in the United States. The company explores for oil and natural gas reserves in the Williston Basin of North Dakota and Montana, and the Green River Basin of Wyoming and Colorado. As of December 31, 2009, it had estimated proved reserves of 3.8 million barrels of oil and 3.8 billion cubic feet of natural gas. The company was formerly known as Columbia Copper Company Ltd. and changed its name to Kodiak Oil & Gas Corp. in September 2001. Kodiak Oil & Gas Corp. was incorporated in 1972 and is headquartered in Denver, Colorado.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net

Contributing Sources